Výsledky vyhledávání

Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data

Autor: Richard Davidson, Susana Banerjee, David M. O'Malley, Rebecca C. Arend, Gráinne H. Long, Kimmie K. McLaurin

Publikováno v: Advances in Therapy

Introduction We aimed to characterize real-world utilization of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in women with ovarian cancer (OC). Methods This retrospective observational study of claims data from US MarketScan® Commercial/Med

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77671a42fa55661fec78398b02f23e4
https://doi.org/10.1007/s12325-021-01959-5

Zobrazit plný text záznamu

Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States

Autor: Dominic Muston, Robert Hettle, Su Zhang, Wei Gao, Kimmie K. McLaurin, Matthew J. Monberg, Elyse Swallow, Kathleen N. Moore, James Signorovitch, Iden Kalemaj

Publikováno v: Gynecologic Oncology. 159:491-497

Objective This study evaluated the cost-effectiveness of olaparib monotherapy in the first-line maintenance setting vs. surveillance in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation from a US third-party payer perspective.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65b6c5a9c2c36cb45e94d7250fb9194f
https://doi.org/10.1016/j.ygyno.2020.08.013

Zobrazit plný text záznamu

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants

Autor: Jumi Yi, Laura L. Swett, Robin M. Pokrzywinski, Melissa Pavilack, Pia S. Pannaraj, Kimmie K. McLaurin, Veena R. Kumar

Publikováno v: Clinical Pediatrics

This study assessed the impact of respiratory syncytial virus-confirmed hospitalizations (RSVH) on caregivers of high-risk preterm infants. Caregivers for infants born at 29 to 35 weeks' gestational age and hospitalized for confirmed RSV disease resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0f7bee2143b1692f7f494004411300
https://doi.org/10.1177/0009922819843639

Zobrazit plný text záznamu

Abstract P1-09-13: A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer

Autor: Tapashi Dalvi, Susan McCutcheon, Kimmie K. McLaurin, Jenna Collins, James Bennett, Beth L. Nordstrom, Brian R. Murphy, Josefa Maria Briceno, Robert Hettle

Publikováno v: Cancer Research. 79:P1-09

Background: Limited data exist on the natural history (treated with standard of care) of metastatic breast cancer (mBC) characterized by germline breast cancer susceptibility gene mutations (gBRCAm). Real-world data examining survival for patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c8808be90db305332c0b8deab8c106e
https://doi.org/10.1158/1538-7445.sabcs18-p1-09-13

Zobrazit plný text záznamu

Abstract P1-09-14: Demographic, clinical/disease characteristics, and treatment of patients with germline mutated metastatic breast cancer: A CancerLinQ study

Autor: S Maclachlan, Kimmie K. McLaurin, Josefa Maria Briceno, Robert Hettle, James Bennett, I Herr, Susan McCutcheon, Tapashi Dalvi

Publikováno v: Cancer Research. 79:P1-09

Objective: To describe the demographics, clinical/disease characteristics and treatment patterns of patients with germline BRCA mutated (gBRCAm) metastatic breast cancer (mBC) as compared to those with gBRCA wild type (wt) and those who are untested

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e52497b1063d42caf11f29733a082c5
https://doi.org/10.1158/1538-7445.sabcs18-p1-09-14

Zobrazit plný text záznamu

Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer

Autor: David M. O'Malley, Rebecca Christian Arend, Naufil Alam, Ozan Ozgoren, Kimmie K. McLaurin, Grainne H. Long, Susana N. Banerjee

Publikováno v: Journal of Clinical Oncology. 40:5552-5552

5552 Background: Tolerability is a key consideration when selecting a PARP inhibitor (PARPi) for ovarian cancer (OC). Here we expand on earlier work (Arend et al 2021) to further characterize real-world tolerability and dose modifications in US patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::389e924fa35a377ac739fedfc879ea7a
https://doi.org/10.1200/jco.2022.40.16_suppl.5552

Zobrazit plný text záznamu

A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status

Autor: James Bennett, Charles McCrea, Susan McCutcheon, Kimmie K. McLaurin, Reshma Shinde, Jenna Collins, Beth L. Nordstrom, Brian R. Murphy, Tapashi Dalvi, Puneet K. Singhal, Josefa Maria Briceno

Publikováno v: Oncology and Therapy

Introduction Limited data exist on real-world treatment patterns and the effectiveness of cyclin-dependent kinase (CDK) 4/6 inhibitors in germline BRCA (gBRCA)-mutated breast cancer. Methods Adults with hormone receptor-positive (HR+), human epiderma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62db719af86d498f97c974902397fe06
https://pubmed.ncbi.nlm.nih.gov/34308518

Zobrazit plný text záznamu

Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer

Autor: Daniel Simmons, Jigna Bhalla, Rebecca L. Stone, Kimmie K. McLaurin, Julia Engstrom-Melnyk

Publikováno v: Gynecologic Oncology. 162:S111-S112

Objectives: Olaparib is approved as a first line (1L) maintenance (mtx) option, as monotherapy for BRCA mutated (BRCAm) ovarian cancer (OC) and in combination with bevacizumab (Bev) for homologous recombination deficient (HRD) OC. Niraparib monothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a3f8d56c6a5e99f66ac1357d32e4743
https://doi.org/10.1016/s0090-8258(21)00854-4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání